(Q44093600)

29 November 2017

title

Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate (English)

1 reference

29 November 2017

Robert Lindsay

2

1 reference

29 November 2017

Zhengqing Li

3

1 reference

29 November 2017

Chandrasekhar Kasibhatla

4

1 reference

29 November 2017

Jacques Brown

5

1 reference

29 November 2017

Nelson B. Watts

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12730756

30 December 2023

language of work or name

English

0 references

publication date

29 April 2003

1 reference

full work available at URL

29 November 2017

http://link.springer.com/content/pdf/10.1007/s00198-003-1401-8.pdf

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1007/S00198-003-1401-8

http://link.springer.com/article/10.1007/s00198-003-1401-8/fulltext.html

30 December 2023

1 reference

https://api.crossref.org/works/10.1007/S00198-003-1401-8

http://link.springer.com/content/pdf/10.1007/s00198-003-1401-8

30 December 2023

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1007/S00198-003-1401-8

Osteoporosis International

30 December 2023

published in

1 reference

29 November 2017

volume

14

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

437-441

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-003-1401-8

29 November 2017

exact match

0 references

cites work

Limitations of randomized clinical trials. Proposed alternative designs

1 reference

12 December 2020

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

The ethics of randomized clinical trials

1 reference

12 December 2020

The combination of randomized and historical controls in clinical trials

1 reference

12 December 2020

The evaluation of therapies: historical control studies

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Identifiers

DOI

1 reference

29 November 2017

1 reference